| 000 | 03197cam a2200529Ki 4500 | ||
|---|---|---|---|
| 001 | 9780429353116 | ||
| 003 | FlBoTFG | ||
| 005 | 20220509193100.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 191120s2019 si o 000 0 eng d | ||
| 040 |
_aOCoLC-P _beng _erda _epn _cOCoLC-P |
||
| 020 |
_a9780429353116 _q(electronic bk.) |
||
| 020 |
_a0429353111 _q(electronic bk.) |
||
| 020 |
_a9781000707441 _q(electronic bk. : Mobipocket) |
||
| 020 |
_a100070744X _q(electronic bk. : Mobipocket) |
||
| 020 |
_a9781000707571 _q(electronic bk. : EPUB) |
||
| 020 |
_a1000707571 _q(electronic bk. : EPUB) |
||
| 020 |
_a9781000707311 _q(electronic bk. : PDF) |
||
| 020 |
_a1000707318 _q(electronic bk. : PDF) |
||
| 020 | _z9789814800808 | ||
| 020 | _z9814800805 | ||
| 035 | _a(OCoLC)1128094396 | ||
| 035 | _a(OCoLC-P)1128094396 | ||
| 050 | 4 | _aTP248.E5 | |
| 072 | 7 |
_aMED _x009000 _2bisacsh |
|
| 072 | 7 |
_aMED _x058170 _2bisacsh |
|
| 072 | 7 |
_aMED _x071000 _2bisacsh |
|
| 072 | 7 |
_aTDCW _2bicssc |
|
| 082 | 0 | 4 |
_a660.634 _223 |
| 245 | 0 | 0 |
_aPharmaceutical biocatalysis : _bchemoenzymatic synthesis of active pharmaceutical ingredients / _cedited by Peter Grunwald. |
| 264 | 1 |
_aSingapore : _bJenny Stanford Publishing, _c2019. |
|
| 300 | _a1 online resource (1 volume.) | ||
| 336 |
_atext _btxt _2rdacontent |
||
| 337 |
_acomputer _bc _2rdamedia |
||
| 338 |
_aonline resource _bcr _2rdacarrier |
||
| 520 | _aThis volume provides an insight into the future strategies for commercial biocatalysis with a focus on sustainable technologies, together with chemoenzymatic and biotechnological approaches to synthesize various types of approved and new active pharmaceutical ingredients (APIs) via proven and latest synthetic routes using single-step biocatalytic or enzyme cascade reactions. Many of these drugs act as enzyme inhibitors, as discussed in a chapter with a variety of examples. The targeted enzymes are involved in diseases such as different cancers, metastatic and infectious diseases, osteoporosis, and cardiovascular disorders. The biocatalysts employed for API synthesis include hydrolytic enzymes, alcohol dehydrogenases, laccases, imine reductases, reductive aminases, peroxygenases, cytochrome P450 enzymes, polyketide synthases, transaminases, and halogenases. Many of them have been improved with respect to their properties by engineering methods. The book discusses the syntheses of drugs, including alkaloids and antibiotics, non-ribosomal peptides, antimalarial and antidiabetic drugs, prenylated xanthones, antioxidants, and many important (chiral) intermediates required for the synthesis of pharmaceuticals. | ||
| 588 | _aOCLC-licensed vendor bibliographic record. | ||
| 650 | 0 |
_aEnzymes _xIndustrial applications. |
|
| 650 | 0 | _aBiocatalysis. | |
| 650 | 0 | _aPharmaceutical chemistry. | |
| 650 | 7 |
_aMEDICAL / Biotechnology _2bisacsh |
|
| 650 | 7 |
_aMEDICAL / Nursing / Pharmacology _2bisacsh |
|
| 650 | 7 |
_aMEDICAL / Pharmacology _2bisacsh |
|
| 700 | 1 |
_aGrunwald, Peter, _d1941- _eeditor. |
|
| 856 | 4 | 0 |
_3Taylor & Francis _uhttps://www.taylorfrancis.com/books/9780429353116 |
| 856 | 4 | 2 |
_3OCLC metadata license agreement _uhttp://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf |
| 999 |
_c129438 _d129438 |
||